The FDA has issued multiple public advisories about kratom, including warnings about contamination in certain kratom products, safety concerns related to its pharmacological effects, import alerts authorizing the detention of kratom shipments at the border, and statements questioning the compound's safety profile. These actions create a regulatory environment that traditional payment processors interpret as hostile to the category, even though none of the FDA's actions have resulted in a federal ban on domestic kratom sales.
Payment processors respond to regulatory signals regardless of whether those signals have resulted in binding legal restrictions. The FDA's public position on kratom is sufficient for most acquirers and card networks to classify the product as high-risk, and their internal risk models do not distinguish between a product that is actively banned and one that is the subject of regulatory concern. For kratom vendors, this means that the FDA's position effectively restricts payment processing access even in the absence of a legal prohibition. 27 Blockchain's kratom payment processing is structured to operate regardless of these regulatory signals because the crypto payment infrastructure does not depend on card network or acquirer risk models.
